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Preeclampsia may be due to an excess of circulating anti-angiogenic growth factors derived from the 
placenta,  but metabolic syndrome-like disorders may also set oﬀ a cascade of placental and systemic 
inﬂammation and oxidative stress.  We present a case of severe superimposed preeclampsia with obe-
sity,  diabetes and a mild imbalance of angiogenic factors,  in which diet therapy ameliorated the 
preeclamptic signs while improving the adiponectin level.  A 41-year-old pregnant woman with obesity 
and diabetes was referred to our hospital because of severe proteinuria and hypertension at 22 weeks 
of gestation.  After administration of insulin and hydralazine with diet therapy,  her hypertension and 
proteinuria were ameliorated with a 15-kg weight loss.  Her adiponectin level was low and her leptin 
level was high,  but her angiogenic factor levels were within the normal ranges for pregnant women at 
admission.  The diet therapy ameliorated her hypertension and proteinuria while improving her adi-
ponectin level as she achieved weight loss.  This case suggests that diet therapy for obese preeclampsia 
patients with a mild imbalance of anti-and pro-angiogenic factors may play an important role in man-
aging preeclampsia.  Measurements of maternal adipocytokines and angiogenic factors may be impor-
tant to distinguish the main cause of preeclampsia,  i.e.,  poor placentation or maternal constitutional 
factors,  for managing preeclampsia in patients with obesity.
Key words: adipocytokine,  angiogenic factor,  diet therapy,  obesity,  preeclampsia
reeclampsia is characterized by the onset of high 
blood pressure and proteinuria.  It occurs in 
about 3-5ｵ of all pregnancies and results in substan-
tial maternal and neonatal morbidity and mortality [1,  
2].  Although the etiology of preeclampsia is still 
unclear,  recent studies suggest that its major pheno-
types,  hypertension and proteinuria,  may be due to an 
excess of circulating anti-angiogenic growth factors 
derived from the placenta [2].  In addition,  insulin 
resistance has been implicated in the pathophysiology 
of preeclampsia.  Types 1 and 2 diabetes,  gestational 
diabetes and polycystic ovarian syndrome are also well 
known to be risk factors for preeclampsia [3].  
Several reports have also demonstrated that a higher 
body mass index (BMI) increases the risk of preec-
lampsia,  suggesting that obesity is an important risk 
factor for preeclampsia [4].  Moreover,  we previously 
demonstrated that insulin resistance with adipocyte 
dysfunction may play a role in the pathophysiology of 
preeclampsia in obese women [5-7].  These data sug-
gested that predisposing cardiovascular or metabolic 
risks for endothelial dysfunction such as insulin resis-
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tance and obesity,  as part of an exaggerated systemic 
inﬂammatory response,  might dominate in the origins 
of maternal preeclampsia [8].  Because we have not 
experienced superimposed preeclampsia patients with 
good responsiveness to the diet therapy for long peri-
ods,  even in cases described in our previous report 
[5],  we present a case of severe superimposed preec-
lampsia with obesity,  diabetes and a mild imbalance of 
antiangiogenic and proangiogenic factors,  in which 
diet therapy ameliorated the preeclamptic symptoms 
associated with improved adipocyte function.
Case Report
　 A 41-year-old obese woman (prepregnant BMI:  
40.0) was referred to our hospital because of severe 
proteinuria and hypertension at 22 weeks of gestation.  
Before the referral to our hospital,  she received sul-
fonylurea,  and her HbA1c was 5.3ｵ,  with mild pro-
teinuria and normal blood pressure.  She had been 
diagnosed with overt diabetes and received insulin 
therapy during a pregnancy at 35 years of age.  During 
that pregnancy,  she had only mild proteinuria without 
hypertension and delivered a healthy female infant 
weighing 3,300g at 39 weeks of gestation.  After the 
previous delivery,  she dropped out of follow-up care 
and received no medication for diabetes,  although her 
weight gain was over 30kg (75 to 109kg).  Her past 
history was unremarkable except for diabetes and 
obesity.  Laboratory data at admission showed normal 
liver and renal function but anemia,  severe protein-
uria (4g/day) and hypertension (188/115mmHg) 
(Table 1).  After the initiation of insulin and hydrala-
zine administration,  her hypertension and proteinuria 
were ameliorated with a 15-kg weight loss with change 
of her dietary calories (from 1,400 to 2,000kcal) to 
avoid ketonuria,  and she took no medication for 
hypertension from 25 weeks of gestation to delivery 
(Fig.  1).  She had moderate non-proliferative diabetic 
retinopathy,  but it was not progressive during this 
pregnancy.  Fetal growth was normal,  and she deliv-
ered a healthy male infant weighing 3,280g at 37 
weeks of gestation.  We did not ﬁnd any evidence of 
hypercalcemia or hypoglycemia in the newborn.  The 
placenta showed almost normal villous morphology.  
Because the patient had moderate to severe proteinu-
ria (1-2g/day) at 6 months after giving birth,  we 
conclude that severe diabetic nephropathy might have 
been present before this pregnancy.
　 We retrospectively examined the patientʼs circulat-
ing adiponectin,  leptin,  antiangiogenic factors (soluble 
fms-like tyrosine kinase 1 (sFlt-1) and soluble Endoglin 
(sEng)) and proangiogenic factor (placental growth 
factor (PlGF) levels) by speciﬁc enzyme-linked immu-
nosorbent assays following the manufacturerʼs instruc-
tions (R&D Systems,  Inc.,  Minneapolis,  MN,  USA) 
using serum that had been stored at －80℃ as 
described in our previous report [5].  All samples 
were examined in duplicate,  and samples for measure-
ment of sFlt-1,  sEng and adiponectin were diluted 
1/100 prior to the assay.  As the patient achieved 
weight loss,  her adiponectin level increased with 
amelioration of the hypertension and proteinuria,  but 
her leptin level remained unchanged during the preg-
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Table 1　 Laboratory data at admission
WBC 8.19　×103/ml Hb 9.2↓　g/dl Plt 377　×103/ml
RBC 2.88↓　×103/ml Ht 25.1↓　% PT 10.8　sec
APTT 27.6　sec AT-III 82　% D-dimer 5.2↑　mg/ml
Fibrinogen 832↑　mg/dl FDP 7.7↑　mg/ml
TP 5.5↓　g/dl ALP 170　IU/l Ca 8.3　mg/dl
Alb 2.5↓　g/dl LAP 86　IU/l Mg 1.6　mg/dl
TTT 1.5　KU γGTP 5　IU/l BUN 7.5　mg/dl
ZTT 4.3　KU CHE 271　IU/l Cr 0.55　mg/dl
T-bil 0.39　mg/dl LDH 248↑　IU/l UA 4.4　mg/dl
D-bil 0.04　mg/dl Na 138　mmol/l T-chol 261↑　mg/dl
AST 13　IU/l K 3.7　mmol/l TG 278　mg/dl
ALT 6　IU/l Cl 107　mmol/l HDL-chol 69　mg/dl
CRP 0.95　mg/dl Hp 60　mg/dl
Urinary protein 4383↑　mg/day 24hCCR 119.4　mi/min eGFR 90.3　ml/min/1.73m2
ANA ＜5.0　index Anti-cardiolipin ab 0.1　U/ml Anti-cardilipin β2 ab ＜1.2　U/ml
nancy (Fig.  1).  The adiponectin level at 22 weeks of 
gestation was lower than the range of obese patients 
with early-onset preeclampsia but was increased and 
eventually was higher than the range of obese patients 
with late-onset preeclampsia,  while the leptin level was 
lower than the range of preeclampsia patients during 
pregnancy,  based on our previous study [5] (Table 
2).  The concentrations of sFlt-1,  PlGF and sEng at 
admission (22 weeks of gestation) were within the 
normal pregnancy ranges for the second trimester,  
based on our previous study [5].  Furthermore,  
although the sFlt-1 and sEng levels were elevated and 
the PlGF level was decreased,  the sFlt-1 and PlGF 
levels were within the normal pregnancy ranges for the 
third trimester and the sEng level was higher than the 
normal pregnancy range for the third trimester,  though 
it was not within the range of late-onset preeclampsia 
(Table 3).  The measurements of adipocytokines and 
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Fig. 1　 Clinical course and maternal concentrations of adipocytokines.
Table 2　 Summary of adipocytokine levels during pregnancy
Patient Normal pregnancy with obesity Preeclampsia Patients with obesity
22w 36w early control late control early onset late onset
Adiponectin (μg/ml)  8.1 27.4 9.0 (6.8-12.1) 8.8 (6.4-10.5) 12.4 (8.3-16.8) 15.8 (12.1-18.3)
Leptin (ng/ml) 31.2 32.6 29.1 (23.5-32.8) 23.7 (18.9-27.6) 56.9 (42.3-70.4) 42.3 (33.1-51.7)
[median (interquartile range)]
Table 3　 Summary of angiogenic factor levels during pregnancy
Patient Normal pregnancy with obesity Preeclampsia Patients with obesity
22w 36w early control late control early onset late onset
sFlt-1 (pg/ml) 744.2 1,733.1 490.4 (244.7-833.2) 1,520.3 (955.7-1,899.2) 6,270.2 (3,980.4-8,003.5) 3,324.0 (2,690.0-4,122.2)
PlGF 650.4 193.6 820.6 (677.4-944.0) 238.8 (180.5-270.2) 64.2 (24.3-111.1) 174.5 (108.8-203.7)
sEng (ng/ml)  10.4 20.2 6.7 (2.7-11.8) 10.4 (5.9-12.8) 90.7 (78.9-108.2) 42.2 (31.9-54.9)
[median (interquartile range)]
angiogenic factors were approved by the Institutional 
Ethical Board of Okayama University Hospital,  and 
the subject provided informed consent for study par-
ticipation.
Discussion
　 Although the cause of preeclampsia remains elu-
sive,  the primary origin of the condition is thought to 
be the placenta.  Placenta-derived factors potentiated 
and may be partly responsible for the maternal syn-
drome of preeclampsia.  The result is a generalized 
endothelial dysfunction manifested by hypertension,  
proteinuria and thrombotic microangiopathy [9].  
Recent studies have demonstrated that altered release 
of antiangiogenic and proangiogenic factors,  such as 
sFlt-1,  PlGF and sEng,  from the placenta may con-
tribute to the pathophysiology of preeclampsia [10,  
11].  In the present case,  we observed only a mild 
imbalance of antiangiogenic and proangiogenic factors,  
and the patientʼs angiogenic factor levels were within 
the normal ranges at admission and were slightly ele-
vated or decreased but not within the ranges of late-
onset preeclampsia at 36 weeks of gestation.  Because 
she might have had severe diabetic nephropathy and 
diabetic retinopathy before this pregnancy,  the renal 
and endothelial dysfunction might have contributed to 
the development of preeclampsia.  Moreover,  elder 
maternal age is a risk factor for preeclampsia through 
age-dependent endothelial dysfunction by maternal 
constitutional factors [4,  11].  These data suggested 
that placenta-derived angiogenic factors may not have 
played an important role and maternal constitutional 
factors may have been dominant in the pathogenesis of 
superimposed preeclampsia in this patient.
　 Adipose tissue expresses various secretory pro-
teins,  such as leptin,  tumor necrosis factor and adi-
ponectin,  that regulate energy expenditure,  lipid 
metabolism and insulin resistance [12].  Abnormal 
adipocytokine levels are often observed in preeclamp-
sia patients.  Placental leptin production is elevated 
under hypoxic conditions [13],  and leptin levels in 
women with preeclampsia are signiﬁcantly higher than 
those in women with normal pregnancies [14-16].  
Leptin derived from the placenta may play a role in the 
pathophysiology of preeclampsia through increased 
insulin resistance,  autonomic activation or direct eﬀects 
on the endothelium as a placenta-derived factor,  as 
well as an angiogenic factor.  Recent reports have also 
demonstrated that plasma adiponectin concentrations 
are not elevated in women with normal pregnancies but 
are paradoxically elevated in women with preeclamp-
sia [17-19].  Furthermore,  signiﬁcant diﬀerences in 
the adiponectin levels have been found between normal 
and overweight women,  but only among those with 
late-onset preeclampsia [5].  Since hypoadiponectine-
mia is associated with impaired endothelium-dependent 
vasodilatation [20,  21] and is an independent risk 
factor for hypertension [22],  adiponectin may main-
tain endothelial function,  and its deﬁciency may lead 
to endothelial dysfunction or hypertension.  In our case,  
the hypertension and proteinuria were ameliorated 
with improved adiponectin levels as the patientʼs 
weight decreased,  suggesting that diet therapy may 
play roles in the pathogenesis of preeclampsia with 
obesity and in the mild imbalance of angiogenic fac-
tors.  Elevated leptin in the serum is mainly derived 
from the placenta,  whereas adiponectin originates from 
adipose tissues [13,  23],  and in our case we observed 
that the adiponectin level was increased but the leptin 
level was not changed under diet therapy.  Although 
the multifactorial pathogenesis of diﬀerent preeclamp-
sia phenotypes has not been fully elucidated,  these 
ﬁndings suggest that measurements of adiponectin and 
angiogenic factor levels may be important for distin-
guishing whether the main cause of preeclampsia is 
poor placentation or maternal constitutional factors,  
in cases of managing preeclampsia with obesity.
　 In the present case,  we observed abnormal adipo-
cytokine levels but a mild imbalance of antiangiogenic 
and proangiogenic factor levels,  and weight loss under 
diet therapy improved the adiponectin level,  resulting 
in amelioration of the preeclamptic symptoms,  blood 
pressure and proteinuria.  These ﬁndings suggest that 
diet therapy for obese preeclampsia patients with a 
mild imbalance of antiangiogenic and proangiogenic 
factors may play an important role in the management 
of preeclampsia as well as diabetes through improved 
adipocyte function.  Furthermore,  measurements of 
maternal adiponectin and antiangiogenic and proangio-
genic factor levels may be important for the manage-
ment of preeclampsia with obesity.
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